|
Volumn 22, Issue 11, 2004, Pages 1343-1346
|
Biogenerics standoff
a
a
NONE
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALTEPLASE;
ANTIDEPRESSANT AGENT;
BIOLOGICAL PRODUCT;
CONJUGATED ESTROGEN;
GENERIC DRUG;
GROWTH HORMONE;
INFLUENZA VACCINE;
INSULIN;
NON PRESCRIPTION DRUG;
PALIVIZUMAB;
PROTEIN;
RECOMBINANT ERYTHROPOIETIN;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
SERMORELIN;
SOMATREM;
BIOEQUIVALENCE;
BIOTECHNOLOGY;
CELL LINE;
DRUG COST;
DRUG SAFETY;
EMPLOYEE;
FERMENTATION;
HEALTH CARE COST;
HEALTH INSURANCE;
HUMAN;
NOTE;
PATENT;
PRESCRIPTION;
PRIORITY JOURNAL;
SUICIDE;
BIOTECHNOLOGY;
DRUG APPROVAL;
DRUG INDUSTRY;
DRUGS, GENERIC;
EUROPEAN UNION;
LEGISLATION, DRUG;
PATENTS;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
EID: 8344281389
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt1104-1343 Document Type: Note |
Times cited : (10)
|
References (8)
|